A Dark Vector Cognition product

Bristol Myers Squibb 10-Q 2026-09-30

BMY · CIK 14272 · Form 10-Q · Period ended September 30, 2026 · Filed October 29, 2026

Revenue rose 6.9% to $13.1 billion. Net income was $2.16 billion.

8 sections, 232K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$13.1B$12.2B+6.9%
Net income$2.16B$2.20B-1.8%
Diluted EPS$1.05$1.08-2.8%
Cash and equivalents$9.57Bn/an/a

From the XBRL facts tagged to this filing; both columns are as reported in this filing.

The 77 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _______

Commission File Number 001-01136


BRISTOL-MYERS SQUIBB COMPANY

(Exact name of registrant as specified in its charter)


Delaware22-0790350
(State or other jurisdiction of incorporation or organization)**(**I.R.S. Employer Identification No.)

Route 206 & Province Line Road, Princeton, New Jersey 08543

(Address of principal executive offices) (Zip Code)

(609) 252-4621

(Registrant’s telephone number, including area code)


(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 Par ValueBMYNew York Stock Exchange
Celgene Contingent Value RightsCELG RTNew York Stock Exchange
2.973% Notes due 2030BMY/30New York Stock Exchange
3.363% Notes due 2033BMY/33New York Stock Exchange
1.750% Notes due 2035BMY35New York Stock Exchange
3.857% Notes due 2038BMY/38New York Stock Exchange
4.289% Notes due 2045BMY/45New York Stock Exchange
4.581% Notes due 2055BMY/55New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒Accelerated filer ☐Non-accelerated filer ☐Smaller reporting company ☐Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At October 21, 2026, there were 2,044,085,831 shares outstanding of the Registrant’s $0.10 par value common stock.

BRISTOL-MYERS SQUIBB COMPANY

INDEX TO FORM 10-Q

September 30, 2026

PART I—FINANCIAL INFORMATION
Item 1.
Financial Statements:
Consolidated Statements of Earnings and Comprehensive Income/(Loss)3
Consolidated Balance Sheets4
Consolidated Statements of Cash Flows5
Notes to Consolidated Financial Statements6
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations28
Item 3.
Quantitative and Qualitative Disclosure About Market Risk45
Item 4.
Controls and Procedures45
PART II—OTHER INFORMATION
Item 1.
Legal Proceedings45

Item 1A. [Risk Factors](ib020f3263f224c05800c3dc29271e849208) [45](ib020f3263f224c05800c3dc29271e849208)

| Risk Factors | | | 45 | | | | | | | | | | Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | | | 45 | | | | | | | | | | Item 5. | Other Information | | | 45 | | | | | | | | | | Item 6. | Exhibits | | | 46 | | | | | | | | | | | Summary of Abbreviated Terms | | | 47 | | | | Signatures | | | 48 | | |

  • Indicates brand names of products which are trademarks not owned by BMS. Specific trademark ownership information is included in the Exhibit Index at the end of this Quarterly Report on Form 10-Q.

PART I—FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENTS OF EARNINGS

Dollars in millions, except per share data

(UNAUDITED)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net product sales$12,606$11,850$36,362$34,645
Alliance and other revenues4633721,1691,047
Total Revenues13,06912,22237,53235,692
Cost of products sold(a)4,1463,43511,2929,839
Selling, general and administrative1,6991,7895,1425,086
Research and development2,3652,5287,9737,365
Acquired IPRD1,5586331,6512,328
Amortization of acquired intangible assets4588311,3322,491
Other (income)/expense, net307(108)279725
Total Expenses10,5339,10827,67027,834
Earnings/(Loss) before income taxes2,5363,1149,8627,858
Income tax provision3749191,7051,888
Net earnings/(loss)2,1622,1958,1565,970
Noncontrolling interest—(6)—3
Net earnings/(loss) attributable to BMS$2,162$2,201$8,156$5,967
Earnings/(Loss) per common share:
Basic$1.06$1.08$4.00$2.93
Diluted1.051.083.982.93

(a) Excludes amortization of acquired intangible assets.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

Dollars in millions

(UNAUDITED)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net earnings/(loss)$2,162$2,195$8,156$5,970
Other comprehensive income/(loss), net of taxes and reclassifications to earnings:
Derivatives qualifying as cash flow hedges(9)4883(395)
Pension and postretirement benefits—19822
Marketable debt securities(4)—(9)2
Foreign currency translation23(26)16096
Total other comprehensive income/(loss)941243(275)
Comprehensive income/(loss)2,1712,2368,3995,695
Comprehensive income/(loss) attributable to noncontrolling interest—(6)—3
Comprehensive income/(loss) attributable to BMS$2,171$2,242$8,399$5,692

The accompanying notes are an integral part of these consolidated financial statements.

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED BALANCE SHEETS

Dollars in millions

(UNAUDITED)

ASSETSSeptember 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents$9,574$10,209
Marketable debt securities3,007464
Receivables10,63911,414
Inventories2,7042,690
Other current assets3,8444,613
Total Current assets29,76729,390
Property, plant and equipment7,9717,543
Goodwill21,73521,754
Other intangible assets16,93619,103
Deferred income taxes5,8845,378
Marketable debt securities378396
Other non-current assets6,0996,474
Total Assets$88,772$90,038
LIABILITIES
Current liabilities:
Short-term debt obligations$1,028$2,261
Accounts payable4,6283,575
Other current liabilities13,09817,581
Total Current liabilities18,75323,417
Deferred income taxes228222
Long-term debt41,84942,850
Other non-current liabilities4,5385,043
Total Liabilities65,36871,533
Commitments and Contingencies (see Note 18)
EQUITY
BMS Shareholders’ equity:
Preferred stock——
Common stock292292
Capital in excess of par value of stock46,67446,387
Accumulated other comprehensive loss(1,281)(1,524)
Retained earnings21,19016,896
Less cost of treasury stock(43,471)(43,579)
Total BMS Shareholders’ equity23,40418,473
Noncontrolling interest—33
Total Equity23,40418,506
Total Liabilities and Equity$88,772$90,038

The accompanying notes are an integral part of these consolidated f

Showing the first 8K of 125K characters. Open the full section

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related footnotes included elsewhere in this Quarterly Report on Form 10-Q to enhance the understanding of our results of operations, financial condition and cash flows. Certain amounts in this Quarterly Report on Form 10-Q may not sum due to rounding. Percentages have been calculated using unrounded amounts.

EXECUTIVE SUMMARY

Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns. Our R&D strategy is designed to invest in the most promising science and to consistently execute in a way that translates that science into new medicines with the highest probability of success. To execute this strategy, we focus on three key priorities: science, execution, and value. Additionally, we are driving commercial execution in our key first-in-class and/or best-in-class marketed products, where we continue to expand and see potential for further expansion into the future. For further information on our strategy, see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Executive Summary—Strategy" in our 2025 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.

In 2026, we have achieved multiple regulatory approvals across our portfolio, including: (i) approval of our first CELMoD, Zenbexus (iberdomide), in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with MM who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent in the U.S.; (ii) approval of Camzyos for pediatric patients with symptomatic oHCM in the U.S.; (iii) approval of Sotyktu for the treatment of adults with active PsA in the U.S. and EU; and (iv) approval of Opdivo for cHL in the U.S. and EU. We have also made meaningful progress advancing our pipeline, highlighted by: (i) topline Phase III results from the ALOFT-IPF study of admilparant in adults with IPF, which met its primary endpoint at the 60 mg dose; (ii) positive topline interim Phase III results from the ACTION-1 study of RYZ101 in patients with SSTR+ GEP-NETs who have progressed following Lu177-based therapy; (iii) FDA acceptance of our NDA for mezigdomide in RRMM with a PDUFA date of May 13, 2027; (iv) positive interim Phase II results from the ROSETTA Lung-02 study of pumitamig in patients with previously untreated advanced NSCLC; (v) positive topline Phase II results from the registrational QUINTESSENTIAL study of arlo-cel in adult patients with quadruple-class exposed RRMM; and (vi) positive interim results from two Phase III studies conducted in China for iza-bren in heavily pretreated, unresectable locally advanced or metastatic TNBC and recurrent or metastatic ESCC.

We continue to view business development as an important component of our strategy, focusing on opportunities where we can add strategic value and deliver returns. In May 2026, we entered into global license agreements with Hengrui to develop and commercialize 13 early stage assets in oncology, hematology and immunology. For additional information relating to this arrangement, refer to "Item 1. Financial Statements — Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements". Additionally, in August 2026, we announced plans to build a new, state-of-the-art multi-modal manufacturing campus in Houston, Texas, and a new, radiopharmaceutical manufacturing facility in Whitestown, Indiana, reflecting our continuing efforts to invest in research and development, technology and domestic production within the U.S.

We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth. As previously announced, our ongoing strategic productivity initiative includes acceleration of the delivery of medicines to patients by evolving and streamlining our enterprise operating model in key areas such as R&D, manufacturing, commercial and other functions. As a result of an expansion in 2025, we expect to realize annual cost savings of approximately $2.0 billion by the end of 2027. The exit costs resulting from these actions are included in our updated 2023 Restructuring Plan.

Financial Highlights

Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions, except per share data2026202520262025
Total Revenues$13,069$12,222$37,532$35,692
Diluted earnings/(loss) per share
GAAP$1.05$1.08$3.98$2.93
Non-GAAP1.351.634.974.89

Revenues increased 7% during the third quarter of 2026 and 5% year-to-date, primarily reflecting higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis, which was partially offset by the impact of generics across the remainder of the Legacy Portfolio*.*

The $0.03 decrease in GAAP EPS for the third quarter of 2026 was primarily due to higher one-time Acquired IPRD charges in 2026 and the expiry of royalty income on diabetes products at the end of 2025, partially offset by lower amortization of acquired intangible assets and higher revenues in 2026. After adjusting for specified items, the $0.28 decrease in non-GAAP EPS was primarily due to the aforementioned higher Acquired IPRD charges and the expiry of royalty income on diabetes products, partially offset by higher revenues.

The $1.05 increase in GAAP EPS year-to-date was primarily due to lower amortization of acquired intangible assets, lower one-time Acquired IPRD charges and higher revenues in 2026, partially offset by the expiry of royalty income on diabetes products at the end of 2025. After adjusting for specified items, the $0.08 increase in non-GAAP EPS was primarily due to the aforementioned lower Acquired IPRD charges and higher revenues, partially offset by the expiry of royalty income on diabetes products.

Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude specified items that represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For further information and reconciliations relating to our non-GAAP financial measures refer to "—Non-GAAP Financial Measures."

Economic and Market Factors

Governmental Actions

Ongoing regulatory focus on prescription

Showing the first 8K of 87K characters. Open the full section

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For a discussion of our market risk, refer to "Item 7A. Quantitative and Qualitative Disclosures about Market Risk" in our 2025 Form 10-K. There have been no material changes to our market risk during the nine months ended September 30, 2026.

Item 4. CONTROLS AND PROCEDURES

Management carried out an evaluation, under the supervision and with the participation of its chief executive officer and chief financial officer, of the effectiveness of the design and operation of its disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of September 30, 2026, such disclosure controls and procedures are effective.

There were no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

Information pertaining to legal proceedings can be found in "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies," to the interim consolidated financial statements, and is incorporated by reference herein.

Item 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in the Company's 2025 Form 10-K.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table summarizes the surrenders of our equity securities during the three months ended September 30, 2026:

PeriodTotal Number of Shares Purchased**(a)**Average Price Paid per Share**(a)**Total Number of Shares Purchased as Part of Publicly Announced Programs**(b)**Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs**(b)**
Dollars in millions, except per share data
July 1 to 31, 202671,019$62.24—$5,014
August 1 to 31, 20267,410$62.94—$5,014
September 1 to 30, 202626,634$66.69—$5,014
Three months ended September 30, 2026105,063—

(a)Includes shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program.

(b)In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of our common stock. From time to time thereafter, the Board approved additional share repurchase authorizations totaling an amount of $25.0 billion, including the most recent authorization of $3.0 billion in December 2023. The remaining share repurchase capacity under the program was $5.0 billion as of September 30, 2026. Our share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time.

Item 5. OTHER INFORMATION

Rule 10b5-1 Trading Arrangement

During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).

Exhibit No.Description
22.Subsidiary Issuers of Guaranteed Securities (incorporated by reference to Exhibit 22 of Bristol Myers Squibb Company's Annual Report on Form 10-K filed on February 11, 2026)
31a.Section 302 Certification Letter (filed herewith).
31b.Section 302 Certification Letter (filed herewith).
32a.Section 906 Certification Letter (furnished herewith).
32b.Section 906 Certification Letter (furnished herewith).
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
  • Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Keytruda and Winrevair are trademarks of Merck; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:

2025 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2025MCLmantle cell lymphoma
2seventy bio2seventy bio, Inc.MerckMerck & Co., Inc., Rahway, NJ, USA
ANDAAbbreviated New Drug ApplicationMFmyelofibrosis
AOCLAccumulated other comprehensive lossMiratiMirati Therapeutics, Inc.
AstraZenecaAstraZeneca PLCMMmultiple myeloma
AVDdoxorubicin, vinblastine and dacarbazineMZLmarginal zone lymphoma
BioArcticBioArctic ABNDANew Drug Application
BioNTechBioNTech SENSCLCnon-small cell lung cancer
CelgeneCelgene CorporationNYHANew York Heart Association
CELMoDcereblon E3 ligase modulatoroHCMObstructive Hypertrophic Cardiomyopathy
CERCLAU.S. Comprehensive Environmental Response, Compensation and Liability ActOnoOno Pharmaceutical Co., Ltd
cHLclassical Hodgkins LymphomaPD-1programmed cell death protein 1
CRCcolorectal cancerPD-L1programmed death-ligand 1
CVRContingent value rightPDUFAPrescription Drug User Fee Act
Dr. Reddy's LaboratoriesDr. Reddy's Laboratories, Limited and Dr. Reddy's Laboratories, Inc.PhilochemPhilochem AG
DVddaratumumab, bortezomib and dexamethasonePfizerPfizer, Inc.
ECEuropean CommissionPFSprogression-free survival
EPSearnings per sharePsApsoriatic arthritis
ESCCesophageal squamous cell carcinomaQuarterly Report on Form 10-QQuarterly Report on Form 10-Q for the quarter ended September 30, 2026
ES-SCLCextensive stage small cell lung cancerR&Dresearch and development
EUEuropean UnionRDFVreadily determinable fair values
EvotecEvotec SEREMSrisk evaluation and mitigation strategy
Exchange Actthe Securities Exchange Act of 1934RocheF. Hoffman-La Roche & Co.
FASBFinancial Accounting Standards BoardRRMMrelapsed or refractory multiple myeloma
FDAU.S. Food and Drug AdministrationSanofiSanofi S.A.
GAAPgenerally accepted accounting principlesSARSpecial Administrative Region
GEP-NETsgastroenteropancreatic neuroendocrine tumorsSECU.S. Securities and Exchange Commission
GTNgross-to-netSPCSupplementary Protection Certificate
HCMhypertrophic cardiomyopathySSTR+somatostatin receptor-positive
HengruiJiangsu Hengrui Pharmaceuticals Co., Ltd.SystImmuneSystImmune, Inc.
HHSHealth and Human ServicesTNBCtriple negative breast cancer
IPFidiopathic pulmonary fibrosisUKUnited Kingdom
IPRDin-process research and developmentU.S.United States
IRAInflation Reduction Act of 2022VATvalue added tax
IRSInternal Revenue ServiceVEGF-AVascular endothelial growth factor A
ITInformation Technology

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT)
Date:October 29, 2026By:/s/ Christopher Boerner, Ph.D.
Christopher Boerner, Ph.D. Chair of the Board and Chief Executive Officer
Date:October 29, 2026By:/s/ David V. Elkins
David V. Elkins Chief Financial Officer